itacitinib (INCB039110) News

12 3 4 5 6 7 8 9 »

||||||||||  dezapelisib (INCB040093) / Incyte
Trial completion date, Trial primary completion date:  Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) -  Jun 3, 2025
P1, N=121, Active, not recruiting,  Sponsor: Incyte Corporation
Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment closed, Enrollment change:  NCI-2022-03765: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants (clinicaltrials.gov) -  May 30, 2025
P2, N=20, Active, not recruiting,  Sponsor: City of Hope Medical Center
Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026 Recruiting --> Active, not recruiting | N=50 --> 20

|||||||||| Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: Subgroup analysis of the ROME trial (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_631;
P2
CGP with MTB-guided TT may identify patients with GI cancer who benefit from targeted therapies not routinely available in clinical practice. The roles of TMB and potential disease-specific thresholds deserve further investigation.

|||||||||| itacitinib (INCB039110) / Incyte
Journal: Wheat germ agglutinin-nanoparticles encapsulating itacitinib target and suppress pro-inflammatory slan+ monocytes. (Pubmed Central) - Apr 28, 2025
Findings support WGA/F127/PNPs as a promising drug delivery system for targeting slan+ monocytes, providing new therapeutic potential for SLE. ITA-loaded WGA/F127/PNPs effectively target and suppress pro-inflammatory slan+ monocytes, presenting a promising, cell-specific therapeutic approach for managing systemic lupus erythematosus and related autoimmune disorders.

|||||||||| itacitinib (INCB039110) / Incyte
A pilot study of Janus kinase 1 (JAK1) inhibitor itacitinib for treatment-refractory sarcomas: Leiomyosarcoma cohort. (Hall A - Posters and Exhibits; Poster Bd #: 29) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2048;
P1
Itacitinib demonstrated durable disease control in patients with LMS and warrants further study in this subtype. While our analysis of markers on paired biopsy samples does not suggest that immunotherapy combinations with itacitinib are likely to be successful for LMS, a more thorough analysis will be presented at the meeting as this data may still suggest potent combination therapies.

|||||||||| itacitinib (INCB039110) / Incyte
Journal, Cytokine release syndrome: Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation. (Pubmed Central) - Mar 27, 2025
P1
Itacitinib, when added to standard GvHD prophylaxis, was well tolerated and resulted in low rates of CRS, acute and chronic GvHD, NRM and encouraging rates of GvHD-free relapse-free survival (GRFS) and OS after haplo-HCT. NCT03755414.

|||||||||| itacitinib (INCB039110) / Incyte
P2 data, Journal: Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. (Pubmed Central) - Mar 16, 2025
P2
Importantly, itacitinib did not impact IEC therapy efficacy (objective response rate at 6 months: 39.1% for itacitinib 200 mg bid vs 26.1% for placebo). Trial registration: clinicaltrials.gov; #NCT04071366.

||||||||||  dezapelisib (INCB040093) / Incyte
Trial completion date, Trial primary completion date:  Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) -  Feb 13, 2025
P1, N=121, Active, not recruiting,  Sponsor: Incyte Corporation
Trial registration: clinicaltrials.gov; #NCT04071366. Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025

|||||||||| itacitinib (INCB039110) / Incyte
Journal: Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform. (Pubmed Central) - Jan 3, 2025
They also inhibited the monocyte's ability to promote T-cell proliferation and inhibited proinflammatory cytokine production. ITA-loaded F127/LEC PNPs showed potential for monocyte-targeted therapy, offering new avenues for disease treatment.

|||||||||| itacitinib (INCB039110) / Incyte
Mechanism of CRS: Critical Roles of IFN-?, CD40L, and CD4 Cells. (HCC Ballroom B; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1334;
P1, P2
Further, Lentiviral overexpression of CD40L in CD8 CART19 resulted in robust surface expression and secretion of CD40L as well as dramatic production of IL-6 by iDC (Data not shown). Together, our studies clearly implicate two major pathways that are necessary and sufficient for CRS: 1) IFN-?/IFN-?R/JAK1/2 axis (both CD4 and CD8) and 2) CD40L/CD40 PI3Kg/d axis (exclusively CD4) and represent logical targets for future CRS mitigation strategies in vivo .

|||||||||| itacitinib (INCB039110) / Incyte
Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial (HCC Ballroom B; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_769;
P2
Based on the activity of ruxolitinib, a Jak inhibitor, in treating GVHD, we reasoned that a Jak inhibitor may prevent GVHD...Thiotepa 5 mg/kg was given on day -7 and fludarabine 30 mg/m 2 on days -6 to -3... These encouraging results warrant further studies to evaluate the role of JAK inhibitors to prevent GVHD, replacing MMF.

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov) -  Dec 13, 2024
P2, N=27, Recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
These encouraging results warrant further studies to evaluate the role of JAK inhibitors to prevent GVHD, replacing MMF. Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Apr 2025

|||||||||| Hemophagocytic Syndrome Associated with CAR-T Cell Therapy () - Dec 7, 2024 - Abstract #ASH2024ASH_9228;
on the use of drugs for cell therapy-related HLH at EBMT centers, common clinical combinations include corticosteroids + chemotherapy, corticosteroids + monoclonal antibodies + chemotherapy, corticosteroids + chemotherapy + cytokine blockade, corticosteroids + cytokine blockade, and corticosteroids alone. We introduce commonly used specific medications, including etoposide, emapalumab, the IL-six monoclonal antibody siltuximab, the anti-interleukin (IL)-six receptor monoclonal antibody tocilizumab, the interleukin-1 receptor antagonist anakinra, and JAK-one and JAK-two blockers such as ruxolitinib and the JAK-one inhibitor itacitinib, among others.

|||||||||| itacitinib (INCB039110) / Incyte
Evaluation of Itacitinib Impact on TNF? Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches () - Dec 7, 2024 - Abstract #ASH2024ASH_9158;
P2
The itacitinib BID dosing regimen was associated with improved TNF? suppression to levels not exceeding the baseline (placebo) during the observation time.

|||||||||| Review, Journal: Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease. (Pubmed Central) - Nov 17, 2024
Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD...For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.

|||||||||| itacitinib (INCB039110) / Incyte
P1 data, Journal, IO biomarker, Metastases: Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). (Pubmed Central) - Nov 16, 2024
P1
Tumor biopsies and blood samples will be taken for presence of JAK1 mutations.Activation of JAK/STAT pathway drives HCC development and is associated with immunotherapy resistance. Itacitinib is hypothesized to be safe and effective in HCC patients that have progressed after first-line therapies.Clinical Trial Registration: EudraCT: 2017-004437-81 NCT04358185 (ClinicalTrials.gov).

||||||||||  itacitinib (INCB039110) / Incyte
Trial primary completion date:  Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) -  Nov 14, 2024
P1/2, N=23, Active, not recruiting,  Sponsor: University of Pennsylvania
Itacitinib is hypothesized to be safe and effective in HCC patients that have progressed after first-line therapies.Clinical Trial Registration: EudraCT: 2017-004437-81 NCT04358185 (ClinicalTrials.gov). Trial primary completion date: Oct 2024 --> May 2024

|||||||||| itacitinib (INCB039110) / Incyte
Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF) (Room 6B (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_1476;
P2
The study met the primary endpoint of 1-year GRFS at 54%, which is compared favorably to Tac/Siro or Tac/methotrexate as GVHD prophylaxis, similar to the results observed in PTCy/tacrolimus/MMF (BMT CTN 1703). The observed aGVHD rate was lower than our previously published historic data in patients receiving Tac/Siro alone (31% vs. 9%), half of the cases with grade 2-4 aGVHD were diagnosed after day +100 when itacitinib administration stopped per protocol therapy, indicating the need for further refinement in tapering strategy of Tac/Siro/itacitinib, potentially guided by the cytokine/cellular biomarkers identified in our study.

||||||||||  parsaclisib (INCB50465) / Incyte
Enrollment closed, Enrollment change:  Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) (clinicaltrials.gov) -  Nov 1, 2024
P2, N=112, Active, not recruiting,  Sponsor: Incyte Corporation
The observed aGVHD rate was lower than our previously published historic data in patients receiving Tac/Siro alone (31% vs. 9%), half of the cases with grade 2-4 aGVHD were diagnosed after day +100 when itacitinib administration stopped per protocol therapy, indicating the need for further refinement in tapering strategy of Tac/Siro/itacitinib, potentially guided by the cytokine/cellular biomarkers identified in our study. Recruiting --> Active, not recruiting | N=200 --> 112

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment change, Trial withdrawal, Trial primary completion date, Adverse events, Checkpoint inhibition:  Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors (clinicaltrials.gov) -  Oct 31, 2024
P2, N=0, Withdrawn,  Sponsor: Douglas Johnson
Recruiting --> Active, not recruiting | N=200 --> 112 N=25 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2026 --> Sep 2026

||||||||||  parsaclisib (INCB50465) / Incyte
Trial completion date, Trial primary completion date:  Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) (clinicaltrials.gov) -  Oct 22, 2024
P2, N=200, Recruiting,  Sponsor: Incyte Corporation
N=25 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2026 --> Sep 2026 Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2027

||||||||||  dezapelisib (INCB040093) / Incyte
Trial completion date, Trial primary completion date:  Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) -  Oct 22, 2024
P1, N=121, Active, not recruiting,  Sponsor: Incyte Corporation
Trial completion date: Sep 2024 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2027 Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant (clinicaltrials.gov) -  Oct 10, 2024
P1, N=8, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025 Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

||||||||||  Campath (alemtuzumab) / Sanofi, itacitinib (INCB039110) / Incyte
Trial completion, Trial completion date, Trial primary completion date:  NCI-2019-03203: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia (clinicaltrials.gov) -  Sep 26, 2024
P1, N=15, Completed,  Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025 Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Sep 2024 | Trial primary completion date: Dec 2026 --> Sep 2024

|||||||||| Strategies to Mitigate CAR T-Cell-Associated Cytokine Release Syndrome and Neurologic Toxicity (Room A (2F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_47;
I will spotlight promising data from a recent clinical trial investigating the JAK-1 inhibitor itacitinib to prevent CRS and ICANS after axi-cel treatment (Frigault et al., ASH Abstract...Lastly, I will share our experience with anakinra to prevent CRS and ICANS in patients with large B-cell lymphoma receiving the CD19 CAR T-cell product lisocabtagene maraleucel on an investigator-initiated clinical trial (Liang et al., Tandem Meeting Abstract...2023). Learning objectives: - Identify clinical and laboratory factors associated with severe CRS and ICANS - Recognize differences in the toxicity profile across distinct CAR T-cell products - Become acquainted with current toxicity prophylactic strategies

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date:  Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov) -  Aug 26, 2024
P2, N=27, Recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Learning objectives: - Identify clinical and laboratory factors associated with severe CRS and ICANS - Recognize differences in the toxicity profile across distinct CAR T-cell products - Become acquainted with current toxicity prophylactic strategies Trial completion date: Nov 2026 --> Dec 2025

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  NCI-2022-03765: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants (clinicaltrials.gov) -  Aug 4, 2024
P2, N=50, Recruiting,  Sponsor: City of Hope Medical Center
Trial completion date: Nov 2026 --> Dec 2025 Trial completion date: Apr 2024 --> May 2026 | Trial primary completion date: Apr 2024 --> May 2026

|||||||||| itacitinib (INCB039110) / Incyte, Keytruda (pembrolizumab) / Merck (MSD)
Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up (20BC) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_870;
P2
Conclusions : Treatment-nai?ve pts with mNSCLC and PD-L1 expression ?50% treated with pembrolizumab and a brief course of JAK inhibition achieved an ORR of 62% at 12 weeks and improvement in mPFS and mOS compared to historical controls (Keynote 24: mPFS 10.3 mo, mOS 30 mo). Interferon signaling modulation through JAK1 inhibition may help prevent resistance to anti-PD1 therapy and should be studied further in a randomized trial.

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion, Trial completion date:  haplo-HCT: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Jun 30, 2024
P1, N=55, Completed,  Sponsor: Washington University School of Medicine
Interferon signaling modulation through JAK1 inhibition may help prevent resistance to anti-PD1 therapy and should be studied further in a randomized trial. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> May 2024

||||||||||  itacitinib (INCB039110) / Incyte
Phase classification, Trial completion date:  Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (clinicaltrials.gov) -  Jun 26, 2024
P2, N=59, Active, not recruiting,  Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> May 2024 Phase classification: P2a --> P2 | Trial completion date: May 2024 --> Dec 2024

|||||||||| itacitinib (INCB039110) / Incyte
Clinical Trial,Phase II, Journal: Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. (Pubmed Central) - Jun 20, 2024
Patients with persistent inflammation refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve the efficacy of anti-PD-1 immunotherapy by pivoting T cell differentiation dynamics.

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov) -  Jun 5, 2024
P2, N=27, Recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Thus, JAK inhibition may improve the efficacy of anti-PD-1 immunotherapy by pivoting T cell differentiation dynamics. Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: Jun 2024 --> Oct 2024

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date, Adverse events, Checkpoint inhibition:  Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors (clinicaltrials.gov) -  May 27, 2024
P2, N=25, Recruiting,  Sponsor: Douglas Johnson
Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: Jun 2024 --> Oct 2024 Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Apr 2026

|||||||||| itacitinib (INCB039110) / Incyte
Unravelling the molecular dynamics of endothelial inflammation states interplay from a proteomic perspective (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1428;
IFN? stimulation induced proteins in a single generic induction pattern over time whereas TNF?-induced proteins showed distinct grouping of

||||||||||  Campath (alemtuzumab) / Sanofi, itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  NCI-2019-03203: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia (clinicaltrials.gov) -  May 8, 2024
P1, N=15, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
stimulation induced proteins in a single generic induction pattern over time whereas TNF?-induced proteins showed distinct grouping of Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026

||||||||||  itacitinib (INCB039110) / Incyte
Trial termination, Metastases:  NCI-2018-00615: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas (clinicaltrials.gov) -  May 7, 2024
P1, N=27, Terminated,  Sponsor: Fred Hutchinson Cancer Center
Active, not recruiting --> Terminated; The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment closed, Enrollment change:  Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant (clinicaltrials.gov) -  Apr 25, 2024
P1, N=8, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit. Recruiting --> Active, not recruiting | N=15 --> 8

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment closed:  Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov) -  Mar 22, 2024
P1, N=31, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=15 --> 8 Recruiting --> Active, not recruiting

||||||||||  dezapelisib (INCB040093) / Incyte
Trial completion date, Trial primary completion date:  Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov) -  Mar 13, 2024
P1, N=121, Active, not recruiting,  Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment open:  Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov) -  Mar 13, 2024
P1, N=31, Recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024 Active, not recruiting --> Recruiting

||||||||||  itacitinib (INCB039110) / Incyte
Phase classification:  Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients (clinicaltrials.gov) -  Mar 12, 2024
P1, N=32, Recruiting,  Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Recruiting Phase classification: P1a/1b --> P1

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment closed:  haplo-HCT: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Mar 12, 2024
P1, N=55, Active, not recruiting,  Sponsor: Washington University School of Medicine
Phase classification: P1a/1b --> P1 Recruiting --> Active, not recruiting

|||||||||| Inrebic (fedratinib) / BMS, Jakafi (ruxolitinib) / Incyte, itacitinib (INCB039110) / Incyte
Preclinical, Journal: Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis. (Pubmed Central) - Mar 6, 2024
Consistent with its superior clinical effects, ruxolitinib exerted the greatest transcriptional changes in CD8 T cells and monocytes, targeting more genes across several biologic pathways, most notably JAK-dependent pro-inflammatory signaling. We conclude that JAK1 inhibition is sufficient to curtail CpG-induced disease, but combined inhibition of JAK1 and JAK2 is needed to best control LCMV-induced immunopathology.

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  haplo-HCT: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Mar 2, 2024
P1, N=55, Recruiting,  Sponsor: Washington University School of Medicine
We conclude that JAK1 inhibition is sufficient to curtail CpG-induced disease, but combined inhibition of JAK1 and JAK2 is needed to best control LCMV-induced immunopathology. Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> Jun 2024

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov) -  Feb 22, 2024
P1, N=30, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> Jun 2024 Trial completion date: Feb 2027 --> Apr 2025 | Trial primary completion date: Feb 2027 --> Apr 2025

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date:  Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) -  Feb 21, 2024
P1/2, N=23, Active, not recruiting,  Sponsor: University of Pennsylvania
Trial completion date: Feb 2027 --> Apr 2025 | Trial primary completion date: Feb 2027 --> Apr 2025 Trial completion date: Jan 2027 --> Jun 2027

||||||||||  itacitinib (INCB039110) / Incyte
Trial completion date, Trial primary completion date:  Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov) -  Feb 15, 2024
P2, N=27, Recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Jan 2027 --> Jun 2027 Trial completion date: Feb 2028 --> May 2026 | Trial primary completion date: Feb 2028 --> Jun 2024

|||||||||| itacitinib (INCB039110) / Incyte
ITACITINIB FOR THE PREVENTION OF IMMUNE EFFECTOR CELL THERAPY (Hall 3 South) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1900;
P2
Incidence of grade 3/4 neutropenia and thrombocytopenia not resolved at Day 28 was higher with itacitinib vs placebo. Severe infection rates were comparable

||||||||||  itacitinib (INCB039110) / Incyte
Enrollment closed:  Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov) -  Feb 13, 2024
P1, N=30, Active, not recruiting,  Sponsor: M.D. Anderson Cancer Center
Severe infection rates were comparable Recruiting --> Active, not recruiting

|||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, itacitinib (INCB039110) / Incyte
Journal: Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response. (Pubmed Central) - Feb 5, 2024
The higher proportion of arachidonic acid in the FA content of ITA-L/M-EVs could be related to the thrombosis described in patients treated with ITA. EVs also induced a decrease in the respiratory burst of neutrophils.



	Diseases Companies Products Productz Mechanisms of Action Sites